Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 6/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.45 |
| ▸ | LMNA | P02545 | 3/20 | 0.44 |
| ▸ | PPID | Q08752 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | MMP8 | P22894 | 1/20 | 0.44 |
| ▸ | MDM2 | Q00987 | 2/20 | 0.43 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.43 |
| ▸ | MDM4 | O15151 | 1/20 | 0.43 |
| ▸ | RECQL | P46063 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11750979 | 0.84 | CA12 (0.56) | MAPTMEN1KMT2ATSHRSMN1; SMN2 | |
| SCHEMBL4065633 | 0.83 | HCAR2 (0.62) | KMT2ASMN1; SMN2ALDH1A1LMNAPOLB | |
| SCHEMBL5113039 | 0.83 | TSHR (0.54) | TSHRALDH1A1LMNAHSD17B10L3MBTL1 | |
| SCHEMBL5817841 | 0.82 | MAPT (0.49) | MAPTMEN1KMT2ASMN1; SMN2L3MBTL1 | |
| SCHEMBL27505937 | 0.82 | MAPT (0.49) | MAPTMEN1KMT2AALDH1A1LMNA | |
| SCHEMBL95660 | 0.82 | MAPT (0.45) | MAPTMEN1KMT2ATSHRSMN1; SMN2 | |
| SCHEMBL6263496 | 0.82 | MAPT (0.57) | MAPTALDH1A1LMNAMDM2HCAR2 | |
| SCHEMBL6263498 | 0.82 | MAPT (0.57) | MAPTALDH1A1LMNAMDM2HCAR2 | |
| SCHEMBL294028 | 0.81 | MAOB (0.43) | MAPTTSHRSMN1; SMN2ALDH1A1LMNA | |
| SCHEMBL27193186 | 0.81 | ALDH1A1 (0.50) | MAPTMEN1KMT2ATSHRALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3051946-A1 | USE OF SUBSTITUTED DIHYDRO-OXINDOLYL SULFONAMIDES, OR THE SALTS THEREOF, FOR INCREASING THE STRESS TOLERANCE OF PLANTS | Bayer CropScience Aktiengesellschaft (DE) | 2016-08-10 | — | — | EP | claimed |
| WO-2015049351-A1 | USE OF SUBSTITUTED DIHYDRO-OXINDOLYL SULFONAMIDES, OR THE SALTS THEREOF, FOR INCREASING THE STRESS TOLERANCE OF PLANTS | BAYER CROPSCIENCE AG (DE) | 2015-04-09 | — | — | WO | claimed |
| WO-2002040449-A1 | DIHYDROISOQUINOLINES AS NOVEL PHOSPHODIESTERASE INHIBITORS | ALTANA PHARMA AG (DE) | 2002-05-23 | — | — | WO | claimed |
| US-5096971-A | Acrylic graft copolymer | MITSUBISHI KASEI CORPORATION (JP) | 1992-03-17 | — | — | US | claimed |
| EP-0366042-A2 | Adsorbent for optical resolution and resolution method employing it | MITSUBISHI KASEI CORPORATION (JP) | 1990-05-02 | — | — | EP | claimed |
| US-4818749-A | Carboxyalkyl dipeptides and medical use thereof in treating hypertension and congestive heart failure | SCHERING CORPORATION (US) | 1989-04-04 | — | — | US | claimed |
| EP-4275752-A2 | TREATMENT OF ADDICTION AND IMPULSE-CONTROL DISORDERS USING PDE7 INHIBITORS | Omeros Corporation (US) | 2023-11-15 | — | — | EP | disclosed |
| US-20230110784-A1 | TREATMENT OF ADDICTION AND IMPULSE-CONTROL DISORDERS USING PDE7 INHIBITORS | OMEROS CORPORATION | 2023-04-13 | — | — | US | disclosed |
| CN-115192711-A | Use of PDE7 inhibitors for the treatment of movement disorders | 奥默罗斯公司 | 2022-10-18 | — | — | CN | disclosed |
| CN-114984229-A | Treatment of addiction and impulse control disorders using PDE7 inhibitors | 奥默罗斯公司 | 2022-09-02 | — | — | CN | disclosed |
| US-11207275-B2 | Treatment of addiction and impulse-control disorders using PDE7 inhibitors | OMEROS CORPORATION (US) | 2021-12-28 | — | — | US | disclosed |
| CN-112168972-A | Treatment of addiction and impulse control disorders using PDE7 inhibitors | 奥默罗斯公司 | 2021-01-05 | — | — | CN | disclosed |
| CN-104758291-B | Use of PDE7 inhibitors for the treatment of movement disorders | 奥默罗斯公司 | 2020-03-03 | — | — | CN | disclosed |
| US-5563162-A | CAN BE ADMINISTERD FOR THE TREATMENT OF ALLERGY, INFLAMMATION, AUTOIMMUNE DISEASES, SHOCK OR PAIN IN ANIMALS AND HUMANS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1996-10-08 | — | — | US | disclosed |
| EP-0622361-A1 | Heterocyclic compounds as bradykinin antagonists | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1994-11-02 | — | — | EP | disclosed |
| CN-1082045-A | Imidazopyridine | MERCK PATENT GMBH (DE) | 1994-02-16 | — | — | CN | disclosed |
| EP-0564960-A1 | Imidazopyridines as angiotensin II antagonists | MERCK PATENT GmbH (DE) | 1993-10-13 | — | — | EP | disclosed |
| US-4785010-A | AGING RESISTANCE OF HUMANS | CASSELLA AKTIENGESELLSCHAFT (DE) | 1988-11-15 | — | — | US | disclosed |
| EP-0124067-B1 | 2-(AMINOALKYL)-PYRROLE DERIVATIVES, PROCESS FOR THEIR MANUFACTURE AND THEIR USE | CASSELLA Aktiengesellschaft (DE) | 1986-12-17 | — | — | EP | disclosed |
| EP-0124067-A1 | 2-(Aminoalkyl)-pyrrole derivatives, process for their manufacture and their use | CASSELLA Aktiengesellschaft (DE) | 1984-11-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11207275-B2 | Treatment of addiction and impulse-control disorders using PDE7 inhibitors | PDE7B, PDE4C, PDE4A | MAPT 3149/4885MEN1 3007/4885KMT2A 786/4885 |
| US-20230110784-A1 | TREATMENT OF ADDICTION AND IMPULSE-CONTROL DISORDERS USING PDE7 INHIBITORS | PDE7B, PDE4C, PDE4A | MAPT 3149/4885MEN1 3007/4885KMT2A 786/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.